Cargando…
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332736/ https://www.ncbi.nlm.nih.gov/pubmed/32620147 http://dx.doi.org/10.1186/s13054-020-03078-z |
| _version_ | 1783553584772677632 |
|---|---|
| author | Doi, Kent Ikeda, Mahoko Hayase, Naoki Moriya, Kyoji Morimura, Naoto |
| author_facet | Doi, Kent Ikeda, Mahoko Hayase, Naoki Moriya, Kyoji Morimura, Naoto |
| author_sort | Doi, Kent |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7332736 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73327362020-07-06 Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series Doi, Kent Ikeda, Mahoko Hayase, Naoki Moriya, Kyoji Morimura, Naoto Crit Care Research Letter BioMed Central 2020-07-03 /pmc/articles/PMC7332736/ /pubmed/32620147 http://dx.doi.org/10.1186/s13054-020-03078-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Research Letter Doi, Kent Ikeda, Mahoko Hayase, Naoki Moriya, Kyoji Morimura, Naoto Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series |
| title | Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series |
| title_full | Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series |
| title_fullStr | Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series |
| title_full_unstemmed | Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series |
| title_short | Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series |
| title_sort | nafamostat mesylate treatment in combination with favipiravir for patients critically ill with covid-19: a case series |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332736/ https://www.ncbi.nlm.nih.gov/pubmed/32620147 http://dx.doi.org/10.1186/s13054-020-03078-z |
| work_keys_str_mv | AT doikent nafamostatmesylatetreatmentincombinationwithfavipiravirforpatientscriticallyillwithcovid19acaseseries AT ikedamahoko nafamostatmesylatetreatmentincombinationwithfavipiravirforpatientscriticallyillwithcovid19acaseseries AT hayasenaoki nafamostatmesylatetreatmentincombinationwithfavipiravirforpatientscriticallyillwithcovid19acaseseries AT moriyakyoji nafamostatmesylatetreatmentincombinationwithfavipiravirforpatientscriticallyillwithcovid19acaseseries AT morimuranaoto nafamostatmesylatetreatmentincombinationwithfavipiravirforpatientscriticallyillwithcovid19acaseseries AT nafamostatmesylatetreatmentincombinationwithfavipiravirforpatientscriticallyillwithcovid19acaseseries |